1. Scrip
  2. >>Therapy Areas

Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?

Partners Keen To Take On Gilead’s Trodelvy

 
• By Andrew McConaghie

Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.

China Beijing Ciftis
AZ and Daiichi Sankyo hope that Dato-DXd can follow in the footsteps of their other ADC, Enhertu, and become an oncology blockbuster. • Source: Shutterstock

AstraZeneca and Daiichi Sankyo will talk to regulators about their promising new Phase III results for datopotamab deruxtecan (Dato-DXd) in the most common form of advanced breast cancer – but may have to hold on for overall survival results before filing.

The companies have revealed that the TROP2-targeted antibody-drug conjugate (ADC) hit its primary endpoint of progression-free survival (PFS) in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.